NeoPharm, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of cancer in the United States. Its product candidates comprise Cintredekin besudotox, a Phase III clinical trial product for the treatment of brain cancer; LE-SN38, a Phase II clinical trial product for the treatment of colorectal cancer and other solid tumors; LEP-ETU, a Phase II clinical trial product for the treatment of breast cancer, lung cancer, ovarian cancer, and other solid tumors; and LErafAON, a Phase I clinical trial product for the treatment of cancer. The company has a license agreement with Nippon Kayaku Co., Ltd., for the...